Recently, FDA announced that it would start its Expedited Access Pathway (EAP) program on April 15, a year after it was proposed.
EAP Program by the FDA is to:
- Speed qualifying devices to patients without compromising FDA’s high standards for safety and effectiveness.
- The program will be available to sponsors from April 15.
- The timeline to respond to such requests is 30 days and if the FDA asks for additional information, the decision cannot be delayed by no later than 30 more days.
- Being an EAP designated project will grant early collaboration for sponsor with CDRH staff to develop a Data Development Plan with the agency.
- The Data Development Plan will allow sponsors to understand the type of data expected and also reduce the burden of premarket data collection to postmarket surveillance.
- EAP designation may also tilt the risk-benefit balance in favor of approval if there is a strong unmet need for the device.
- If enough information is not provided within this timeframe, FDA will deny the EAP request.
Other News
ErlySign Oral Cancer Detection Technology Gets CDSCO Nod
ErlySign, a Nagpur-based biotech startup, has received approval from the Central Drugs Standard Control Organization (CDSCO) to conduct large-scale clinical trials for its novel oral cancer detection technology. The approval for ErlySign follows a rigorous […]
Read MoreAdditional Steps Announced by FDA to Modernize Clinical Trials
The U.S. Food and Drug Administration has made draft guidance available with updated recommendations for good clinical practices (GCPs), which are intended to modernize the clinical trial design and conduct while maintaining data integrity and […]
Read MoreAccreditation and Registration Numbers for Foreign Manufacturers Publication by PMDA
This article deals In accordance with the Pharmaceuticals and Medical Devices Act (PMD Act) of Japan, foreign businesses that wish to produce pharmaceuticals, quackery products, active pharmaceutical ingredients (APIs), or medical devices abroad and import […]
Read MoreBSI New Certification to Mitigate Antimicrobial Resistance Risk in Antibiotic Manufacturing
BSI, the business improvement and standards company, has developed a new certification to mitigate the risk of antimicrobial resistance (AMR) in antibiotic manufacturing. The certification, called the Minimized Risk of Antimicrobial Resistance (AMR) certification, will […]
Read More
TUV SUD Inspects IVD Medical Devices’ Cyber Security
The growing digital connectivity of medical infrastructure is resulting in complicated systems with a plethora of diverse interfaces that are potentially vulnerable to assault. The IVD requires producers to provide proof of cyber security before […]
Read More
TGA Supports MHRA’s New Regulations
The TGA made a commitment to support the MHRA‘s new Regulations worldwide recognition framework for pharmaceuticals. Following the UK’s exit from the European Union, a new international recognition framework for medicines has been developed specifically […]
Read MoreMedical Devices with Extended CE Certification Are Now Accepted On The UK Market
The MHRA revised its guidelines to make clear its stance and reflect its intention to extend the acceptance of CE-marked medical devices on the British market beyond June 30th, 2023. A statutory document that will […]
Read More
The NMPA Enhanced Regulation of Cosmetic Medicine
According to a representative of the State Administration for Market Regulation, after the industry’s quick development, prominent issues like unethical medical practices, fake goods, false advertising, and price fraud emerged, endangering the health and interests […]
Read More
